Pieris Pharmaceuticals Files 8-K

TL;DR

Pieris Pharma filed an 8-K, standard SEC update, no major news yet.

AI Summary

Pieris Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, reporting other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.

Why It Matters

This filing indicates Pieris Pharmaceuticals is providing updates to the SEC, which could relate to ongoing operations or financial reporting.

Risk Assessment

Risk Level: low — The filing is a routine SEC disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• PIERIS PHARMACEUTICALS, INC. (company) — Registrant
• October 3, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 225 Franklin Street, 26th Floor (address) — Principal Executive Offices
• Boston, MA (location) — Principal Executive Offices City and State
• 857-246-8998 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share PIRS The Nasdaq
• $2.6 million — pment awarded Palvella a grant of up to $2.6 million over four years to support the ongoing

Filing Documents

• pirs20241003_8k.htm (8-K) — 37KB
• ex_729446.htm (EX-99.1) — 19KB
• 0001437749-24-030559.txt ( ) — 194KB
• pirs-20241003.xsd (EX-101.SCH) — 3KB
• pirs-20241003_def.xml (EX-101.DEF) — 11KB
• pirs-20241003_lab.xml (EX-101.LAB) — 15KB
• pirs-20241003_pre.xml (EX-101.PRE) — 11KB
• pirs20241003_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. As previously announced, on July 23, 2024, Pieris Pharmaceuticals, Inc., a Nevada corporation ("Pieris"), Polo Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Pieris ("Merger Sub"), and Palvella Therapeutics, Inc., a Delaware corporation ("Palvella"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Palvella, with Palvella continuing as a wholly-owned subsidiary of Pieris and the surviving corporation of the merger. On October 3, 2024, Palvella published a press release announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development awarded Palvella a grant of up to $2.6 million over four years to support the ongoing Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K and the exhibits attached hereto contain forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning the Company, Palvella Therapeutics, Inc. ("Palvella"), the proposed transactions, and other matters. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and the Company, as well as assumptions made by, and information currently available to, management of Palvella and the Company. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release, dated October 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PIERIS PHARMACEUTICALS, INC. Dated: October 3, 2024 /s/ Tom Bures Tom Bures Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR